Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H2 2016’, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS)

The report reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics and enlists all their major and minor projects

The report assesses Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

AdAlta Ltd

Advanced Genetic Systems Inc

Akshaya Bio Inc

AlbaJuna Therapeutics

Allergan Plc

Altor BioScience Corp

Altravax Inc

Amarna Therapeutics BV

American Gene Technologies International Inc

Amunix Operating Inc

Antigen Express Inc

Aphios Corp

Apotex Inc

Argos Therapeutics Inc

Arno Therapeutics Inc

Atreca Inc

B Cell Design SAS

BioClonetics Immunotherapeutics Inc

Biological Mimetics Inc

Biosantech SA

Biotron Ltd

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Bristol-Myers Squibb Company

C4X Discovery Holdings PLC

Calimmune Inc

CEL-SCI Corp

Celgene Corp

Celldex Therapeutics Inc

Chipscreen Biosciences Ltd

CompleGen Inc

ConjuChem LLC

ContraVir Pharmaceuticals Inc

Critical Outcome Technologies Inc

Curevac AG

Cytodyn Inc

Dong-A Socio Holdings Co Ltd

Enzo Biochem Inc

EpiVax Inc

eTheRNA Immunotherapies NV

Etubics Corp

Evofem Inc

FIT Biotech Oy

Formune SL

Fountain Biopharma Inc

Frontier Biotechnologies Co Ltd

Galmed Pharmaceuticals Ltd

GeneCure LLC

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Globeimmune Inc

GW Pharmaceuticals Plc

H-Phar SA

Hadasit Medical Research Services & Development Ltd

Hanmi Pharmaceuticals Co Ltd

Heat Biologics Inc

ID Pharma Co Ltd

IGXBio Inc

Immune Response BioPharma Inc

Immune Therapeutics Inc

ImmunoClin Corp

Immunocore Ltd

Immunotope Inc

ImQuest Life Sciences Inc

InnaVirVax SA

Innovative Targeting Solutions Inc

Inovio Pharmaceuticals Inc

Japan Tobacco Inc

Johnson & Johnson

Karyopharm Therapeutics Inc

KPI Therapeutics Inc

Kymab Ltd

Longevity Biotech Inc

MacroGenics Inc

Medestea Research & Production SpA

Medivir AB

Merck & Co Inc

Mologen AG

Mymetics Corp

Myrexis Inc

NanoViricides Inc

Navigen Pharmaceuticals Inc

NeED Pharma srl

New World Laboratories Inc

Novartis AG

Omeros Corp

Oncolys BioPharma Inc

OncoNOx ApS

Oncovir Inc

Orbis Biosciences Inc

Osel Inc

OyaGen Inc

PaxVax Inc

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharis Biotec GmbH

PharmatrophiX Inc

Phoenix Biotechnology Inc

PlantForm Corp

Profectus BioSciences Inc

RAPID Pharmaceuticals AG

ReceptoPharm Inc

Recombio SL

Relmada Therapeutics Inc

Rodos BioTarget GmbH

Samjin Pharmaceutical Co Ltd

Sangamo BioSciences Inc

Sanofi

Sanofi Pasteur SA

Savoy Pharmaceuticals Inc

Serometrix LLC

Sigma-Tau SpA

Sirenas Marine Discovery LLC

Solon Eiendom ASA

Spider Biotech

Spring Bank Pharmaceuticals Inc

Staidson (Beijing) Biopharmaceuticals Co Ltd

Starpharma Holdings Ltd

Sumagen Co Ltd

Susavion Biosciences Inc

Taiga Biotechnologies Inc

TaiMed Biologics Inc

Takara Bio Inc

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

TeneoBio Inc

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Ltd

TGV-Laboratories

Theratechnologies Inc

Theravectys SA

Tomegavax Inc

Transgene Biotek Ltd

TVAX Biomedical Inc

United Biomedical Inc

Vaccibody AS

Vault Pharma Inc

VDA Pharma Inc

VG Life Sciences Inc

Vichem Chemie Research Ltd

ViiV Healthcare Ltd

Viriom Ltd

ViroStatics srl

XL-protein GmbH

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Human Immunodeficiency Virus (HIV) Infections (AIDS) Overview 11

Therapeutics Development 12

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics under Development by Companies 14

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics under Investigation by Universities/Institutes 27

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Products Glance 33

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Products under Development by Companies 37

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Products under Investigation by Universities/Institutes 57

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development 67

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment 214

Drug Profiles 244

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects 864

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products 912

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones 919

Appendix 930

List of Tables

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2016 57

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS) – Comparative Analysis, H2 2016 58

Number of Products under Development by Companies, H2 2016 60

Number of Products under Development by Companies, H2 2016 (Contd..1) 61

Number of Products under Development by Companies, H2 2016 (Contd..2) 62

Number of Products under Development by Companies, H2 2016 (Contd..3) 63

Number of Products under Development by Companies, H2 2016 (Contd..4) 64

Number of Products under Development by Companies, H2 2016 (Contd..5) 65

Number of Products under Development by Companies, H2 2016 (Contd..6) 66

Number of Products under Development by Companies, H2 2016 (Contd..7) 67

Number of Products under Development by Companies, H2 2016 (Contd..8) 68

Number of Products under Development by Companies, H2 2016 (Contd..9) 69

Number of Products under Development by Companies, H2 2016 (Contd..10) 70

Number of Products under Development by Companies, H2 2016 (Contd..11) 71

Number of Products under Investigation by Universities/Institutes, H2 2016 72

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 73

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 74

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 75

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 76

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 77

Comparative Analysis by Late Stage Development, H2 2016 78

Comparative Analysis by Clinical Stage Development, H2 2016 79

Comparative Analysis by Early Stage Development, H2 2016 80

Comparative Analysis by Unknown Stage Development, H2 2016 81

Products under Development by Companies, H2 2016 82

Products under Development by Companies, H2 2016 (Contd..1) 83

Products under Development by Companies, H2 2016 (Contd..2) 84

Products under Development by Companies, H2 2016 (Contd..3) 85

Products under Development by Companies, H2 2016 (Contd..4) 86

Products under Development by Companies, H2 2016 (Contd..5) 87

Products under Development by Companies, H2 2016 (Contd..6) 88

Products under Development by Companies, H2 2016 (Contd..7) 89

Products under Development by Companies, H2 2016 (Contd..8) 90

Products under Development by Companies, H2 2016 (Contd..9) 91

Products under Development by Companies, H2 2016 (Contd..10) 92

Products under Development by Companies, H2 2016 (Contd..11) 93

Products under Development by Companies, H2 2016 (Contd..12) 94

Products under Development by Companies, H2 2016 (Contd..13) 95

Products under Development by Companies, H2 2016 (Contd..14) 96

Products under Development by Companies, H2 2016 (Contd..15) 97

Products under Development by Companies, H2 2016 (Contd..16) 98

Products under Development by Companies, H2 2016 (Contd..17) 99

Products under Development by Companies, H2 2016 (Contd..18) 100

Products under Development by Companies, H2 2016 (Contd..19) 101

Products under Investigation by Universities/Institutes, H2 2016 102

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 103

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 104

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 105

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 106

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 107

Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 108

Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 109

Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 110

Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 111

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Abivax SA, H2 2016 112

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by AdAlta Ltd, H2 2016 113

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Advanced Genetic Systems Inc, H2 2016 114

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Akshaya Bio Inc, H2 2016 115

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by AlbaJuna Therapeutics, H2 2016 116

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Allergan Plc, H2 2016 117

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Altor BioScience Corp, H2 2016 118

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Altravax Inc, H2 2016 119

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Amarna Therapeutics BV, H2 2016 120

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by American Gene Technologies International Inc, H2 2016 121

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Amunix Operating Inc, H2 2016 122

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Antigen Express Inc, H2 2016 123

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Aphios Corp, H2 2016 124

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Apotex Inc, H2 2016 125

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Argos Therapeutics Inc, H2 2016 126

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Arno Therapeutics Inc, H2 2016 127

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Atreca Inc, H2 2016 128

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by B Cell Design SAS, H2 2016 129

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by BioClonetics Immunotherapeutics Inc, H2 2016 130

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Biological Mimetics Inc, H2 2016 131

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Biosantech SA, H2 2016 132

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Biotron Ltd, H2 2016 133

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 134

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Bolder Biotechnology Inc, H2 2016 135

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Bristol-Myers Squibb Company, H2 2016 136

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by C4X Discovery Holdings PLC, H2 2016 137

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Calimmune Inc, H2 2016 138

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by CEL-SCI Corp, H2 2016 139

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Celgene Corp, H2 2016 140

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Celldex Therapeutics Inc, H2 2016 141

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Chipscreen Biosciences Ltd, H2 2016 142

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by CompleGen Inc, H2 2016 143

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ConjuChem LLC, H2 2016 144

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 145

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Critical Outcome Technologies Inc, H2 2016 146

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Curevac AG, H2 2016 147

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Cytodyn Inc, H2 2016 148

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 149

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Enzo Biochem Inc, H2 2016 150

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by EpiVax Inc, H2 2016 151

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by eTheRNA Immunotherapies NV, H2 2016 152

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Etubics Corp, H2 2016 153

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Evofem Inc, H2 2016 154

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by FIT Biotech Oy, H2 2016 155

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Formune SL, H2 2016 156

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Fountain Biopharma Inc, H2 2016 157

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Frontier Biotechnologies Co Ltd, H2 2016 158

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Galmed Pharmaceuticals Ltd, H2 2016 159

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GeneCure LLC, H2 2016 160

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GeoVax Labs Inc, H2 2016 161

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Gilead Sciences Inc, H2 2016 162

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GlaxoSmithKline Plc, H2 2016 163

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Globeimmune Inc, H2 2016 164

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GW Pharmaceuticals Plc, H2 2016 165

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by H-Phar SA, H2 2016 166

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 167

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 168

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Heat Biologics Inc, H2 2016 169

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ID Pharma Co Ltd, H2 2016 170

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by IGXBio Inc, H2 2016 171

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immune Response BioPharma Inc, H2 2016 172

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immune Therapeutics Inc, H2 2016 173

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ImmunoClin Corp, H2 2016 174

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immunocore Ltd, H2 2016 175

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immunotope Inc, H2 2016 176

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ImQuest Life Sciences Inc, H2 2016 177

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by InnaVirVax SA, H2 2016 178

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Innovative Targeting Solutions Inc, H2 2016 179

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 180

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Japan Tobacco Inc, H2 2016 181

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Johnson & Johnson, H2 2016 182

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Karyopharm Therapeutics Inc, H2 2016 183

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by KPI Therapeutics Inc, H2 2016 184

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Kymab Ltd, H2 2016 185

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Longevity Biotech Inc, H2 2016 186

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by MacroGenics Inc, H2 2016 187

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Medestea Research & Production SpA, H2 2016 188

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Medivir AB, H2 2016 189

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Merck & Co Inc, H2 2016 190

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Mologen AG, H2 2016 191

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Mymetics Corp, H2 2016 192

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Myrexis Inc, H2 2016 193

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by NanoViricides Inc, H2 2016 194

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Navigen Pharmaceuticals Inc, H2 2016 195

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by NeED Pharma srl, H2 2016 196

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by New World Laboratories Inc, H2 2016 197

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Novartis AG, H2 2016 198

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Omeros Corp, H2 2016 199

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Oncolys BioPharma Inc, H2 2016 200

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by OncoNOx ApS, H2 2016 201

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Oncovir Inc, H2 2016 202

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Orbis Biosciences Inc, H2 2016 203

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Osel Inc, H2 2016 204

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by OyaGen Inc, H2 2016 205

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by PaxVax Inc, H2 2016 206

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 207

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Pfizer Inc, H2 2016 208

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Pharis Biotec GmbH, H2 2016 209

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by PharmatrophiX Inc, H2 2016 210

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Phoenix Biotechnology Inc, H2 2016 211

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by PlantForm Corp, H2 2016 212

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Profectus BioSciences Inc, H2 2016 213

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by RAPID Pharmaceuticals AG, H2 2016 214

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ReceptoPharm Inc, H2 2016 215

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Recombio SL, H2 2016 216

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Relmada Therapeutics Inc, H2 2016 217

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Rodos BioTarget GmbH, H2 2016 218

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 219

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sangamo BioSciences Inc, H2 2016 220

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sanofi, H2 2016 221

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sanofi Pasteur SA, H2 2016 222

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Savoy Pharmaceuticals Inc, H2 2016 223

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Serometrix LLC, H2 2016 224

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sigma-Tau SpA, H2 2016 225

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sirenas Marine Discovery LLC, H2 2016 226

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Solon Eiendom ASA, H2 2016 227

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Spider Biotech, H2 2016 228

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 229

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, H2 2016 230

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Starpharma Holdings Ltd, H2 2016 231

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sumagen Co Ltd, H2 2016 232

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Susavion Biosciences Inc, H2 2016 233

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Taiga Biotechnologies Inc, H2 2016 234

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TaiMed Biologics Inc, H2 2016 235

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Takara Bio Inc, H2 2016 236

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 237

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TechnoVax Inc, H2 2016 238

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TeneoBio Inc, H2 2016 239

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TetraLogic Pharmaceuticals, H2 2016 240

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 241

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TGV-Laboratories, H2 2016 242

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Theratechnologies Inc, H2 2016 243

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Theravectys SA, H2 2016 244

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Tomegavax Inc, H2 2016 245

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Transgene Biotek Ltd, H2 2016 246

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TVAX Biomedical Inc, H2 2016 247

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by United Biomedical Inc, H2 2016 248

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Vaccibody AS, H2 2016 249

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Vault Pharma Inc, H2 2016 250

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by VDA Pharma Inc, H2 2016 251

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by VG Life Sciences Inc, H2 2016 252

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Vichem Chemie Research Ltd, H2 2016 253

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ViiV Healthcare Ltd, H2 2016 254

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Viriom Ltd, H2 2016 255

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ViroStatics srl, H2 2016 256

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by XL-protein GmbH, H2 2016 257

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 258

Assessment by Monotherapy Products, H2 2016 259

Assessment by Combination Products, H2 2016 260

Number of Products by Stage and Target, H2 2016 262

Number of Products by Stage and Mechanism of Action, H2 2016 274

Number of Products by Stage and Route of Administration, H2 2016 286

Number of Products by Stage and Molecule Type, H2 2016 288

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H2 2016 909

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..1), H2 2016 910

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..2), H2 2016 911

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..3), H2 2016 912

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..4), H2 2016 913

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..5), H2 2016 914

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..6), H2 2016 915

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..7), H2 2016 916

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..8), H2 2016 917

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..9), H2 2016 918

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..10), H2 2016 919

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..11), H2 2016 920

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..12), H2 2016 921

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..13), H2 2016 922

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..14), H2 2016 923

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..15), H2 2016 924

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..16), H2 2016 925

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..17), H2 2016 926

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..18), H2 2016 927

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..19), H2 2016 928

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..20), H2 2016 929

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..21), H2 2016 930

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..22), H2 2016 931

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..23), H2 2016 932

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..24), H2 2016 933

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..25), H2 2016 934

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..26), H2 2016 935

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..27), H2 2016 936

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..28), H2 2016 937

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..29), H2 2016 938

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..30), H2 2016 939

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..31), H2 2016 940

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..32), H2 2016 941

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..33), H2 2016 942

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..34), H2 2016 943

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..35), H2 2016 944

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..36), H2 2016 945

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..37), H2 2016 946

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..38), H2 2016 947

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..39), H2 2016 948

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..40), H2 2016 949

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..41), H2 2016 950

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..42), H2 2016 951

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..43), H2 2016 952

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..44), H2 2016 953

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..45), H2 2016 954

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..46), H2 2016 955

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects (Contd..47), H2 2016 956

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, H2 2016 957

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products (Contd..1), H2 2016 958

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products (Contd..2), H2 2016 959

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products (Contd..3), H2 2016 960

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products (Contd..4), H2 2016 961

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products (Contd..5), H2 2016 962

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products (Contd..6), H2 2016 9

List of Figures

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2016 57

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS) – Comparative Analysis, H2 2016 58

Number of Products under Development by Companies, H2 2016 59

Number of Products under Investigation by Universities/Institutes, H2 2016 72

Comparative Analysis by Late Stage Development, H2 2016 78

Comparative Analysis by Clinical Stage Development, H2 2016 79

Comparative Analysis by Early Stage Products, H2 2016 80

Assessment by Monotherapy Products, H2 2016 259

Assessment by Combination Products, H2 2016 260

Number of Products by Top 10 Targets, H2 2016 261

Number of Products by Stage and Top 10 Targets, H2 2016 261

Number of Products by Top 10 Mechanism of Actions, H2 2016 273

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 273

Number of Products by Top 10 Routes of Administration, H2 2016 285

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 285

Number of Products by Top 10 Molecule Types, H2 2016 287

Number of Products by Stage and Top 10 Molecule Types, H2 2016 287

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports